Renewable Therapy Potential of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Idiopathic Pulmonary Fibrosis

Aloysius Krishartadi Damar Bawono; Gasela Zalianti Balqis; Rais Amaral Haq; Ratna Dewi Puspita Sari; Winda Trijayanthi Utama; Suryani Agustina Daulay

doi:10.37034/medinftech.v2i2.34

Authors

Aloysius Krishartadi Damar Bawono University of Lampung
Gasela Zalianti Balqis University of Lampung
Rais Amaral Haq University of Lampung
Ratna Dewi Puspita Sari University of Lampung
Winda Trijayanthi Utama University of Lampung
Suryani Agustina Daulay University of Lampung

DOI:

https://doi.org/10.37034/medinftech.v2i2.34

Keywords:

Anti-fibrotic, Allogeneic, Bone Marrow Derived, Idiopathic Pulmonary Fibrosis, Mesenchymal Stem Cell, Renewable Therapy

Abstract

Idiopathic pulmonary fibrosis (IPF) is a rare chronic respiratory disease characterized by progressive fibrotic changes in lung tissue of unknown origin, resulting in severe decline in lung function and poor prognosis with a median survival of 3 to 5 years. Current pharmacological therapies, including nintedanib and pirfenidone, aim to slow disease progression but are limited by side effects and lack of efficacy in reversing established fibrosis. This literature review explores emerging therapeutic approaches for IPF using data from PubMed, Google Scholar, and ScienceDirect databases. The review highlights mesenchymal stem cell (MSC) therapy, specifically allogeneic bone marrow-derived MSCs, as a promising option. MSC therapy demonstrates superior efficacy in improving forced vital capacity (FVC) by 3.7%, surpassing the effects of nintedanib (3.3%) and pirfenidone (-4.8%), while exhibiting minimal adverse effects. The findings underscore the potential of MSC therapy as a renewable treatment option for IPF, suggesting a paradigm shift towards addressing both disease progression and lung function restoration in affected individuals.

Downloads

Download data is not yet available.

References

S. Yang, P. Liu, Y. Jiang, Z. Wang, H. Dai, and C. Wang, “Therapeutic applications of mesenchymal stem cells in idiopathic pulmonary fibrosis,” Frontiers in Cell and Developmental Biology, vol. 9, Mar. 2021, doi: 10.3389/fcell.2021.639657.

L. Richeldi et al., “Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension,” Thorax, vol. 73, no. 6, pp. 581–583, Oct. 2017, doi: 10.1136/thoraxjnl-2016-209701.

F. Luppi, M. Kalluri, P. Faverio, M. Kreuter, and G. Ferrara, “Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management,” Respiratory Research, vol. 22, no. 1, Apr. 2021, doi: 10.1186/s12931-021-01711-1.

T. M. Dempsey, S. Payne, L. Sangaralingham, X. Yao, N. D. Shah, and A. H. Limper, “Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis,” Annals of the American Thoracic Society, vol. 18, no. 7, pp. 1121–1128, Jul. 2021, doi: 10.1513/annalsats.202007-901oc.

P. Millan-Billi, C. Serra, A. A. Leon, and D. Castillo, “Comorbidities, Complications and Non-Pharmacologic treatment in idiopathic pulmonary fibrosis,” Medical Sciences, vol. 6, no. 3, p. 59, Jul. 2018, doi: 10.3390/medsci6030059.

D. O. Ria, S. Suradi, J. Aphridasari, R. Reviono, and D. Indarto, “The Test of DLCO Is A Valuable Predictor for Prognostic Determination of Patients with Chronic Obstructive Pulmonary Disease,” Jurnal Respirologi Indonesia, vol. 38, no. 2, pp. 83–92, Apr. 2018, doi: 10.36497/jri.v38i2.162.

K. A. Powers and A. S. Dhamoon, “Physiology, pulmonary ventilation and perfusion,” StatPearls - NCBI Bookshelf, Jan. 23, 2023. https://www.ncbi.nlm.nih.gov/books/NBK539907/

R. Deterding et al., “Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease,” ERJ Open Research, vol. 7, no. 2, pp. 00805–02020, Mar. 2021, doi: 10.1183/23120541.00805-2020.

V. Hadda and R. Guleria, “Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?,” Indian Journal of Medical Research, vol. 152, no. 3, p. 177, Jan. 2020, doi: 10.4103/ijmr.ijmr_90_20.

M. Chianese et al., “Pirfenidone and nintedanib in pulmonary fibrosis: Lights and Shadows,” Pharmaceuticals, vol. 17, no. 6, p. 709, May 2024, doi: 10.3390/ph17060709.

B. L. Yen, M. L. Yen, L. T. Wang, K. J. Liu, and H. K. Sytwu, “Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19,” Stem Cells Translational Medicine, vol. 9, no. 10, pp. 1163–1173, Jun. 2020, doi: 10.1002/sctm.20-0186.

A. Averyanov et al., “First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline,” Stem Cells Translational Medicine, vol. 9, no. 1, pp. 6–16, Oct. 2019, doi: 10.1002/sctm.19-0037.

M. Najar et al., “Mesenchymal Stromal Cell-Based Therapy: New Perspectives and Challenges,” Journal of Clinical Medicine, vol. 8, no. 5, p. 626, May 2019, doi: 10.3390/jcm8050626.

Q. Lu and A. H. K. El-Hashash, “Cell-based therapy for idiopathic pulmonary fibrosis,” Stem Cell Investigation, vol. 6, p. 22, Aug. 2019, doi: 10.21037/sci.2019.06.09.

A. Ajit and I. A. Gopalankutty, “Adipose-derived stem cell secretome as a cell-free product for cutaneous wound healing,” 3 Biotech, vol. 11, no. 9, Aug. 2021, doi: 10.1007/s13205-021-02958-7.

M. Khajvand-Abedini et al., “The Restoring Effect of Human Umbilical Cord-Derived Mesenchymal Cell-Conditioned Medium (hMSC-CM) against Carbon Tetrachloride-Induced Pulmonary Fibrosis in Male Wistar Rats,” International Journal of Inflammation, vol. 2022, pp. 1–10, Dec. 2022, doi: 10.1155/2022/7179766.

K. R. Flaherty et al., “Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 52, no. 2, p. 1800230, June. 2018, doi: 10.1183/13993003.00230-2018.

S. D. Nathan et al., “Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment,” Respiratory Medicine, vol. 153, pp. 44–51, Jul. 2019, doi: 10.1016/j.rmed.2019.04.016.

M. K. Glassberg et al., “Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER),” Chest, vol. 151, no. 5, pp. 971–981, May 2017, doi: 10.1016/j.chest.2016.10.061.

K. Kim, S. Bou-Ghannam, S. Kameishi, M. Oka, D. W. Grainger, and T. Okano, “Allogeneic mesenchymal stem cell sheet therapy: A new frontier in drug delivery systems,” Journal of Controlled Release, vol. 330, pp. 696–704, Feb. 2021, doi: 10.1016/j.jconrel.2020.12.028

G. Sgalla, B. Iovene, M. Calvello, M. Ori, F. Varone, and L. Richeldi, “Idiopathic pulmonary fibrosis: pathogenesis and management,” Respiratory Research, vol. 19, no. 1, Feb. 2018, doi: 10.1186/s12931-018-0730-2.

Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. American journal of respiratory and critical care medicine. 2016 Jan 15;193(2):178-85.

Chianese M, Screm G, Salton F, Confalonieri P, Trotta L, Barbieri M, Ruggero L, Mari M, Reccardini N, Geri P, Hughes M. Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows. Pharmaceuticals. 2024 May 30;17(6):709.

P. V. Shah, P. Balani, A. R. Lopez, C. M. N. Nobleza, M. Siddiqui, and S. Khan, “A review of pirfenidone as an Anti-Fibrotic in idiopathic pulmonary fibrosis and its probable role in other diseases,” Curēus, Jan. 2021, doi: 10.7759/cureus.12482.

L. Vietri et al., “Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena,” Therapeutic Advances in Respiratory Disease, vol. 14, p. 175346662090632, Jan. 2020, doi: 10.1177/1753466620906326.